Myasthenia gravis following IFIN-α-2a treatment

European Neurology

Volumn 38, Issue 1, 1997, Pages 68-

  Bora, I ^a   Karli N ^a   Bakar, M ^a   Zarifoglu M ^a   Turan, F ^a   Ogul E ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; HUMAN; KIDNEY CARCINOMA; MALE; MOTOR UNIT POTENTIAL; MYASTHENIA GRAVIS; NEUTROPENIA; PRIORITY JOURNAL;

AUTOIMMUNITY; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; MYASTHENIA GRAVIS;

EID: 0030786546     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000112905     Document Type: Article

References (6)

1. Drachman DB: Myasthenia gravis. N Engl J Med 1994,330:25:1797-1810.
2. Burman P, Karlsson A, Oberg K, Aim GV: Autoimmune thyroid disease in interferon-treated patients. Lancet 1985;ii: 100-101.
3. Rönnblom LE, Alm GV, Oberg K: Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991;30:537-540.
4. Bankhurst AD: Interferons and SLE. J Rheumatol 1987:14(suppl 13):63-67.
5. Batocchi AP, Evoli A, Scrvidei J, Palmisoni MT, Apollo F, Tonali P: Myasthenia gravis during interferon alpha thcrapv. Neurology 1995;45:382-383.
6. Chung YH, Shong YK: Development of autoimmunity after administration of recombinant human interferon alpha 2b for chronic viral hepatitis. J Gastroenterol 1993;88:244-247.